Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473901 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01473901 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT01473901, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This clinical study will assess the doses of BKM120 appropriate for patients with newly diagnosed glioblastoma when given in combination with radiotherapy and temozolomide.
Interventions
- DRUG BKM120 + temozolomide
- DRUG BKM120 +temozolomide with/without radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-12-30 |
| Est. Completion | 2017-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473901
The ClinicalTrials.gov registry entry for NCT01473901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BKM120 + temozolomide is the first listed.
NCT01473901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473901 about?
NCT01473901 is a clinical study titled "A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma". This clinical study will assess the doses of BKM120 appropriate for patients with newly diagnosed glioblastoma when given in combination with radiotherapy and temozolomide.
What is the current status of trial NCT01473901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2011-12-30. Estimated completion is 2017-05-17.
What interventions are being tested in trial NCT01473901?
The interventions under investigation include: BKM120 + temozolomide (DRUG), BKM120 +temozolomide with/without radiotherapy (DRUG).
Who is sponsoring clinical trial NCT01473901?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.